Top Information Technology Stocks To Watch For 2014

General Motors Headquarters. Courtesy of GM media photos.

General Motors (NYSE: GM  ) lags behind its crosstown rival Ford (NYSE: F  ) in one major aspect: profitability. Despite being far ahead in global sales, GM couldn't top Ford's bottom-line income during its first-quarter report. That's mainly because Ford has worked tirelessly on fixing its bottom line by cutting costs in its global operations ��and it's worked extremely well. GM is taking notes on Ford's success and has recently unveiled a state of the art $130 million data center that will be an information technology system to base its global decisions on. GM believes it will give the company what it needs to work faster and smarter to improve vehicle quality and profits. Let's look at why investors are excited and how much this could bring to GM's bottom line.

Better decisions equal better profits
Here's what GM Chairman and CEO Dan Akerson had to say in a press release: "Having a single nerve center for our global operations will get newer vehicle designs and technologies into our customers' hands quicker and improve the bottom line ... IT is back home where it should be, and it further drives unnecessary complexity from our businesses while improving our operational efficiency and better supporting our business strategy."�

Best Biotech Companies To Watch In Right Now: Inovio Pharmaceuticals Inc (INO)

Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int��.

Inovio�� Solution

The Company�� synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company�� synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deoxyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company�� synthetic vaccines are designed to generate specific antibody and/or T-cell responses.

The Company�� SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.

Cancer Synthetic Vaccines

The Company has two broad types of cancer vaccines: preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body�� natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.

Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females��ages 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.

Inovio�� VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).

In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.

Infectious Disease Synthetic Vaccines

In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio�� PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.

The Company�� VGX-3400X targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season�� new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.

Animal Health/Veterinary

VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.

The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Inovio Pharmaceuticals (NYSE: INO) was also up, gaining 10.53 percent to $3.57 after the company received the ��est Theraputic Vaccine��award at the World Vaccine Congress after the close Wednesday.

Top Information Technology Stocks To Watch For 2014: S&P 500/Barra Value(SU)

Suncor Energy Inc., together with its subsidiaries, operates as an integrated energy company. The company involves in the development of petroleum resource basins in Canada's Athabasca oil sands; acquisition, exploration, development, production, and marketing of crude oil and natural gas in Canada and internationally; transportation and refining of crude oil; and marketing of petroleum and petrochemical products primarily in Canada. Its Oil Sands segment produces bitumen recovered from oil sands through mining and in-situ technology, and upgrades it into refinery feedstock, diesel fuel, and by-products. This segment?s products include gasoline and distillates. The company?s Natural Gas segment acquires, explores, develops, and produces natural gas, natural gas liquids, oil, and by-products from reserves located primarily in western Canada, the Northwest Territories, Alaska, and the Arctic Islands. Its International and Offshore segment engages in the exploration and pro duction of oil and gas in offshore Newfoundland and Labrador, in the North Sea, and in Libya and Syria. The company?s Refining and Marketing segment refines crude oil at Suncor's refineries in Edmonton, Alberta; Montreal, Quebec; and Sarnia, Ontario in Canada, as well as in Commerce City, Colorado into a range of petroleum and petrochemical products for sale to retail, commercial, and industrial customers. It also transports crude oil through pipelines in eastern and western Canada, as well as through wholly-owned pipelines in Wyoming and Colorado; and produces specialty lubricants and waxes. In addition, this segment operates retail sites in Canada under the Petro-Canada brand; and in Colorado under Phillips 66 and Shell brands. Suncor Energy Inc. also engages in third-party energy trading activities. The company was formerly known as Suncor Inc. and changed its name to Suncor Energy Inc. in April 1997. Suncor Energy Inc. was founded in 1953 and is headquartered in Calgary , Canada.

Advisors' Opinion:

• [By Selena Maranjian]

  Suncor Energy (NYSE: SU  ) shed 4%, and yields 1.8%. It's Canada's largest energy company, with expertise in deep oil sands. The company recently canceled its plans to upgrade its Voyageur plant in northern Alberta, due in part to competitive pressures. Thus, it will likely just ship more oil to refiners to do much of the processing work. The company is vulnerable to possible tightened regulations due to the recent pipeline oil spill in Arkansas. Some like its diversification beyond North America.

Top Information Technology Stocks To Watch For 2014: iShares Short Treasury Bond ETF (SHV)

iShares Lehman Short Treasury Bond Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the short-term sector of the United States Treasury market as defined by the Lehman Brothers Short U.S. Treasury Index (the Index). The Index includes all publicly issued United States Treasury securities that have a remaining maturity of between 1 and 12 months, and have more than $250 million or more of outstanding face value. In addition, the securities must be denominated in United States dollars, and must be fixed-rate and non-convertible securities. Excluded from the Index are certain special issues, such as flower bonds, targeted investor notes, and state and local government series bonds (SLG5), and coupon issues that have been stripped from assets that are already included in the Index.

The Index is a market capitalization-weighted index. The Fund generally will invest at least 95% of its assets in the United States Government bonds. The Fund invests in a representative sample of the securities in the Index, which has a similar investment profile as the Index. The Fund�� investment advisor is Barclays Global Fund Advisor.

Advisors' Opinion:

• [By Donald van Deventer]

  Shorter-duration Treasury Exchange-Traded Funds: (SHY), (SHV), (IEI), (BIL), (TUZ), (FIVZ), (DTUL), (VGSH), (DTUS), (DFVS), (DFVL), (SST), (ISTB), (TBZ).

Top Information Technology Stocks To Watch For 2014: Sagent Pharmaceuticals Inc.(SGNT)

Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in the United States. It offers a range of products across anti-infective, oncolytic, and critical care indications in various presentations, including single-and multi-dose vials, pre-filled ready-to-use syringes, and premix bags. The company?s anti-infective products include Levofloxacin, a fluoroquinolone antibacterial for the treatment of various infections caused by susceptible bacteria in adults of age 18 years or older; and Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structure, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients. Its oncology products comprise Gemcitabine, a nucleoside metabolic inhibitor used for the treatment of ovarian, breast, lung, and panc reatic cancers; and Topotecan, a topoisomerase inhibitor for small cell lung cancer sensitive disease. The company also offers critical care products consisting of Adenosine, an antiarrhythmic used for the treatment of cardiac rhythm disturbances; and Heparin, an anticoagulant used to prevent and treat blood clotting during and after surgery and dialysis. As of December 31, 2011, it marketed 33 generic injectable products; and had a new product pipeline that included 36 products represented by 63 Abbreviated New Drug Applications (ANDAs). The company sells its products to pharmaceutical wholesale companies, which then distribute the products to end-user hospitals, long-term care facilities, alternate care sites, and clinics. The company was formerly known as Sagent Holding Co. and changed its name to Sagent Pharmaceuticals, Inc. in April 2011. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.

Advisors' Opinion:

• [By James Brumley]

  In no particular order…

  Sagent Pharmaceuticals (SGNT)

  Though Sagent Pharmaceuticals (SGNT) makes a few dozen generic drugs and has a similar number in the works, odds are good most investors couldn’t name a single one of them… and that’s a good thing for anyone on the hunt for cheap stocks from the pharma world.

• [By John Seward]

  Among the changes announced Tuesday, Affiliated Managers Group (NYSE AMG) will replace Forest Laboratories Inc. (NYSE: FRX) in the S&P 500 after the close of trading on Monday, June 30. LaSalle Hotel Properties (NYSE: LHO) will replace Affiliated Managers in the S&P MidCap 400 and Sagent Pharmaceuticals Inc. (NASDAQ: SGNT) will replace LaSalle in the S&P SmallCap 600.

• [By Rich Smith]

  Sagent Pharmaceuticals (NASDAQ: SGNT  ) �is recalling three lots of Vecuronium Bromide for Injection, 10mg (NDC number 25021-657-10). Vecuronium Bromide for Injection is a neuromuscular blocking agent used in addition to general anesthesia to facilitate insertion of endotracheal tubes, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.�

Top Information Technology Stocks To Watch For 2014: American Water Works(AWK)

American Water Works Company, Inc. provides water and wastewater services to residential, commercial, industrial, public, and other customers in the United States and Canada. As of December 31, 2010, the company served approximately 15 million people with drinking water, wastewater, and other water-related services in approximately 30 states and 2 Canadian provinces. It owned approximately 90 surface water treatment plants, 600 groundwater treatment plants, 1,200 groundwater wells, 60 wastewater treatment facilities, 1,300 treated water storage facilities, 1,300 pumping stations and 100 dams, and 49,000 miles of mains and collection pipes. American Water Works Company also enters into public/private partnerships, including operation and maintenance contracts; and design, build, and operate contracts for the provision of services to water and wastewater facilities for municipalities and the United States military. In addition, it enters into contracts to operate and maintai n water and wastewater facilities for the United States military, municipalities, the food and beverage industry, and other customers; and provides services to domestic homeowners to protect against the cost of repairing broken or leaking pipes inside and outside their homes. Further, the company provides biosolids management, transport, and disposal services to municipal and industrial customers. Additionally, it offers granular carbon technologies and products for cleansing water and wastewater, wastewater residuals management services, and water and wastewater facility engineering services. The company was founded in 1886 and is based in Voorhees, New Jersey.

Advisors' Opinion:

• [By Jon C. Ogg]

  American Water Works Company Inc. (NYSE: AWK) is the go-to stock for water investors, which is about as defensive as an investor can get. It is the largest public water utility in America, with around 14 million customers located in 40 states. Yet its market cap is only $8 billion. The water utility giant does not sound cheap at more than 18 times expected earnings, but this stock rarely has looked cheap because of its key market position. Trading at $45.00, it has a 52-week range of $38.70 to $45.48, and its consensus price target is $48.85. Investors also get a 2.5% dividend yield here.

• [By David Dittman]

  Answer: Water utilities have great track records of dividend growth: Aqua America, American Water Works Co Inc (NYSE: AWK) and Connecticut Water Service Inc (NSDQ: CTWS).

Top Information Technology Stocks To Watch For 2014: Ishares Trust Russell 1000 (IWF)

iShares Russell 1000 Growth Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the large-capitalization growth sector of the United States equity market, as represented by the Russell 1000 Growth Index (the Growth Index). The Growth Index is a subset of the Russell 1000 Index. The Index is capitalization weighted, and consists of those companies, or portion of a company, with higher price-to-book ratios and higher forecasted growth within the Russell 1000 Index. The Growth Index represents approximately 49% of the total market capitalization of the Russell 1000 Index.

The Fund invests in a representative sample of securities included in the Growth Index that collectively has an investment profile similar to the Growth Index. iShares Russell 1000 Growth Index Fund's investment advisor is Barclays Global Fund Advisors.

Advisors' Opinion:

• [By James Brumley]

  It’s been especially untrue the last few years. Since this point in the year back in 2003, the iShares Russell 1000 Growth Fund (IWF) has advanced 81%, while the iShares Russell 1000 Value Fund (IWD) has only advanced 67%.

Top Information Technology Stocks To Watch For 2014: General Growth Properties Inc. (GGP)

General Growth Properties, Inc is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in owning, managing, leasing, and redeveloping high-quality regional malls. General Growth Properties, Inc was founded in 1986 and is based in Chicago, Illinois.

Advisors' Opinion:

• [By Adam Levine-Weinberg]

  I think J.C. Penney's best bet for generating cash is selling off a few of its most desirable stores. This is not a palatable strategy, as it means losing some of the highest-potential stores, but it could produce cash without severely diluting the interests of J.C. Penney shareholders or adding interest expense that J.C. Penney cannot afford. For example, Sears Holdings,�another struggling department store giant, was able to sell 11 stores to General Growth Properties (NYSE: GGP  ) for $270 million last year. Bill Ackman's Pershing Square hedge fund happens to be a major shareholder in General Growth.� This could open up an opportunity for J.C. Penney to pursue a similar deal -- if any of its real estate would be sufficiently valuable to General Growth.

• [By Dan Caplinger]

  Admittedly, Sears has had some success raising cash with outright sales of its assets. Last year, for instance, Sears sold nearly a dozen lucrative properties, including its crown-jewel Ala Moana location in Hawaii, to General Growth Properties (NYSE: GGP  ) for $270 million. As Fool contributor Adam Levine-Weinberg noted earlier today, the fact that major J.C. Penney investor Bill Ackman also has a big position in General Growth Properties boosts the odds that a potential deal will go through.

• [By Will Ashworth]

  REITs such as Simon Property Group (SPG) and General Growth Properties (GGP) have enterprise values that are 20 times EBITDA, while LTM stock putters along at slightly less than nine times EBITDA.

• [By Marshall Hargrave]

  Another one of Ackman's biggest wins, and a stock he still owns, is General Growth Properties (NYSE: GGP). Ackman snatched up GGP shares for $0.35 back in 2008 when the mall operator was struggling to stay out of bankruptcy. Since then, the stock has made Ackman nearly 100 times his invesment.